186 related articles for article (PubMed ID: 30789887)
1. The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis.
Millar JA
N Z Med J; 2019 Feb; 132(1490):36-41. PubMed ID: 30789887
[TBL] [Abstract][Full Text] [Related]
2. ▼Teriflunomide for multiple sclerosis.
Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
5. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
[TBL] [Abstract][Full Text] [Related]
6. From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
Aly L; Hemmer B; Korn T
Curr Neuropharmacol; 2017; 15(6):874-891. PubMed ID: 27928949
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.
Xu Y; Mao N; Chirikov V; Du F; Yeh YC; Liu L; Liu R; Gao X
Clin Drug Investig; 2019 Mar; 39(3):331-340. PubMed ID: 30684251
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide: a review of its use in relapsing multiple sclerosis.
Garnock-Jones KP
CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.
Condé S; Moisset X; Pereira B; Zuel M; Colamarino R; Maillet-Vioud M; Lauxerois M; Taithe F; Clavelou P;
Eur J Neurol; 2019 Mar; 26(3):460-467. PubMed ID: 30320947
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
13. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Scott LJ
Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
[TBL] [Abstract][Full Text] [Related]
14. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Landais A; Alhendi R; Gouverneur A; Teron-Aboud B
Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH
Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW;
Mult Scler; 2018 Apr; 24(4):535-539. PubMed ID: 28304217
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
[TBL] [Abstract][Full Text] [Related]
19. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
[TBL] [Abstract][Full Text] [Related]
20. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
Rule GS; Rockwood AL; Johnson-Davis KL
Methods Mol Biol; 2019; 1872():75-83. PubMed ID: 30350281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]